logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11571476 B1

PDFFull Text
Date of Patent:
Feb. 07, 2023

Filed:

Dec. 11, 2017

Anti-tumor/anti-tumor associated fibroblast/anti-hapten trispecific antibodies and use thereof

Applicant:

Taipei Medical University, Taipei, TW;

Inventors:

Ming-Thau Sheu, Taipei, TW;

Yuan-Soon Ho, New Taipei, TW;

Kuo-Hsiang Chuang, New Taipei, TW;

Michael Chen, Hsinchu County, TW;

Assignee:

TAIPEI MEDICAL UNIVERSITY, Taipei, TW;

Attorneys:

WPAT, P.C., Intellectual Property Attorneys

Anthony King

Primary Examiner:

Mark Halvorson

Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 47/68 (2017.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01); C07K 16/28 (2006.01); A61K 47/69 (2017.01); C07K 16/44 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 39/3955 (2013.01); A61K 47/6855 (2017.08); A61K 47/6869 (2017.08); A61K 47/6913 (2017.08); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C07K 16/3069 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C07K 16/44 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01);
Abstract

The present invention relates to an anti-tumor/anti-tumor-associated fibroblast (TAF)/anti-hapten trispecific antibody (TsAb). The anti-hapten domain enables TsAb to arm various hapten-conjugated anti-cancer drugs (nanocarrier drugs, small molecule drugs, protein drugs, and radioactive drugs). The anti-tumor domain enables TsAb-armed drugs to target tumor cells, while the anti-TAF domain enables the TsAb-armed drugs to target TAFs. The present invention allows the simultaneous killing of tumor cells and TAFs by various drugs through arming with TsAb.

Find Patent Forward Citations

Loading…